EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical Characteristics and Outcomes of Patients with Lymphangioleiomyomatosis

Hee-Young Yoon, Sung Woo Park, Jong Sun Park, Byoung Soo Kwon, Yong Suk Jo, Yangjin Jegal, Ju Hyun Oh, Joo Hun Park, Jae Ha Lee, Hongseok Yoo, Bo-Guen Kim, Tae Hun Kim und 3 weitere

Lung · 2026

DOI: 10.1007/s00408-026-00944-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Lung, 2026. Verfasst von Hee-Young Yoon und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis, Lung Neoplasms, Lung. Die Arbeit nennt 32 Literaturangaben. Gefördert von: the Korean Academy of Tuberculosis and Respiratory Diseases, National Research Foundation of Korea, Korea Ministry of Environment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease that affects women of reproductive age. Although registries from Western countries have provided key insights, comprehensive nationwide data from Asian countries are scarce. This study aimed to characterise the clinical, functional and outcome features of Korean patients with LAM from a nationwide multicentre registry. METHODS: We analyzed data from patients with LAM enrolled in the Korean Nationwide Rare Interstitial Lung Disease Registry in 2024. Data on clinical and functional characteristics were collected from 20 centers. Longitudinal changes in pulmonary function were assessed using linear mixed-effects models. Individual annual forced expiratory volume in 1 s (FEV1) change rates were estimated using linear regression and analyzed to identify associated factors. RESULTS: Eighty-six women (mean age, 47.3 years) were included; 50% were asymptomatic at diagnosis and 61.6% had complications, including pneumothorax (29.1%) and renal angiomyolipoma (25.6%). Baseline mean forced vital capacity (FVC) and FEV1 were relatively preserved (89.6% and 78.7% predicted, respectively), whereas diffusing capacity for carbon monoxide was mildly reduced (64.3% predicted). Longitudinal analysis revealed no significant overall decline in lung function. However, cough at presentation and higher baseline FEV1 or FVC were independently associated with disease progression. A total of 54.7% of patients received mechanistic target of rapamycin (mTOR) inhibitors, but no statistically significant differences in the rate of functional decline were observed between users and non-users. CONCLUSION: This study provides a nationwide characterization of LAM in Korea, showing preserved lung function at diagnosis and frequent mTOR inhibitor use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphangioleiomyomatosisLung NeoplasmsLungHumansFemaleMiddle AgedForced Expiratory VolumeVital CapacityAdultRegistriesRepublic of KoreaCoughPulmonary Diffusing CapacityPneumothoraxDisease ProgressionMTOR InhibitorsRespiratory Function Tests

Stichwörter der Autor:innen

LymphangioleiomyomatosisMulticenter studiesPulmonary function testsRare diseasesRegistries

Substanzen

MTOR Inhibitors

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
  • Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
  • Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon, Republic of Korea.

Förderung

  • the Korean Academy of Tuberculosis and Respiratory Diseases
  • National Research Foundation of Korea
  • Korea Ministry of Environment
  • RS-2022-KE002197

Zitieren

APA

Yoon, H. Y., Park, S. W., Park, J. S., Kwon, B. S., Jo, Y. S., Jegal, Y., Oh, J. H., Park, J. H., Lee, J. H., Yoo, H., Kim, B. G., Kim, T. H., Park, J. K., Woo, A., & Song, J. W. (2026). Clinical Characteristics and Outcomes of Patients with Lymphangioleiomyomatosis. Lung. https://doi.org/10.1007/s00408-026-00944-5

Vancouver

Yoon HY, Park SW, Park JS, Kwon BS, Jo YS, Jegal Y, et al. Clinical Characteristics and Outcomes of Patients with Lymphangioleiomyomatosis. Lung. 2026. doi:10.1007/s00408-026-00944-5

BibTeX
@article{Yoon2026,
  author = {Yoon, Hee-Young and Park, Sung Woo and Park, Jong Sun and Kwon, Byoung Soo and Jo, Yong Suk and Jegal, Yangjin and Oh, Ju Hyun and Park, Joo Hun and Lee, Jae Ha and Yoo, Hongseok and Kim, Bo-Guen and Kim, Tae Hun and Park, Jin Kyung and Woo, Ala and Song, Jin Woo},
  title = {Clinical Characteristics and Outcomes of Patients with Lymphangioleiomyomatosis},
  journal = {Lung},
  year = {2026},
  doi = {10.1007/s00408-026-00944-5}
}
Kostenlos starten →